POLYMYALGIA RHEUMATICA

What is polymyalgia rheumatica (PMR)?
Polymyalgia rheumatica (PMR) is a rare inflammatory disease that affects older adults, causing widespread muscle pain and stiffness, especially around the shoulders and hips. Most people who develop PMR are in their 60s or 70s. PMR is closely linked with giant cell arteritis (GCA), a type of vasculitis characterized by inflammation of the arteries in the head and temples, resulting in headaches and vision problems. Left untreated, GCA can lead to blindness and stroke. The two diseases can occur at the same time in the same person. Approximately 20 percent of people with PMR develop GCA, while about half of patients with GCA also have symptoms of PMR.

PMR primarily affects the shoulders, neck, hips, lower back, and thighs, with muscle pain and stiffness that is worse in the morning. A systemic disease (affecting the whole body), PMR also causes flu-like symptoms, such as fatigue and fever. Rarely, PMR causes inflammation of the body’s largest artery, the aorta. This can lead to a potentially life-threatening aortic aneurysm, an abnormal bulging of the weakened vessel that can burst.

The symptoms of PMR can come on suddenly, over a period of days or weeks. Corticosteroid medications such as prednisone are prescribed to reduce inflammation and pain. Patients usually respond quickly, within 24 to 48 hours, but most need to remain on treatment for a year or more. The disease typically runs its course in one to five years. However, even with effective treatment, relapses can occur, so ongoing medical follow-up is essential.

Because of the disease association with GCA, it is important to see your doctor right away if you develop headaches, tenderness in the temples, changes in vision, jaw pain, or fever.

Causes
The exact cause of PMR is unknown. Like vasculitis, it is thought to be an autoimmune disorder, a disease which occurs when the body’s natural defense system mistakenly attacks healthy tissue. Researchers believe genetics and environmental factors may play a role in the onset of PMR. Rarely, the disease occurs in an individual who has cancer. New cases of PMR often occur seasonally, suggesting that a virus may play a role in triggering the disease.

Who gets polymyalgia rheumatica?
PMR is considered a common cause of aching and stiffness in older adults. The average age of patients is about 70, and PMR almost never affects people younger than 50. Women get PMR almost twice as often as men. PMR is the second-most common rheumatic disease after rheumatoid arthritis (RA).

In the United States, disease prevalence is estimated at 50 people per 100,000 per year, and it affects Caucasians more than any other ethnic group. Internationally, prevalence varies country by country. People of Northern European and Scandinavian descent have the highest risk of getting the disease.
POLYMYALGIA RHEUMATICA

How are PMR and GCA related?
For reasons that are not well-understood, PMR and GCA are considered linked inflammatory conditions that often occur together but affect different parts of the body. They are frequently discussed together because of their close association.

Symptoms
The symptoms of PMR often start suddenly and include pain, aching and stiffness in the shoulders, neck, upper arms, hips, lower back and thighs. Symptoms are worse in the morning, or after inactivity. Other common symptoms include:

- Low-grade temperature
- Weight loss
- Loss of appetite
- Limited range of motion in joints
- Fatigue
- General flu-like feeling

Complications
Left untreated, PMR can interfere with mobility, making it difficult to perform daily activities such as dressing, bathing, combing hair, standing up from a couch and getting in and out of a car. Raising the arms over the head can be especially difficult. Very rarely, PMR can cause inflammation of the aorta, the artery which carries blood from the heart to the rest of the body. This can lead to a potentially life-threatening aortic aneurysm.

Serious complications of PMR can also occur when patients develop GCA, which causes narrowing of the arteries in the head and the temples, resulting in persistent headaches, scalp tenderness and vision changes. Without treatment, GCA can result in stroke or blindness.

Diagnosis
There is no single test for diagnosing PMR, so your doctor will consider a number of factors, including a detailed medical history; physical examination; laboratory tests; and, less frequently, imaging studies. Your doctor should also look for symptoms and signs of GCA.

Part of the diagnosis involves ruling out diseases that may cause similar symptoms, such as RA, other forms of vasculitis, infections, other muscle diseases, or cancer. To make an accurate diagnosis of PMR, the following tests may be ordered:

- Blood tests: Common tests include a complete blood cell count, erythrocyte sedimentation rate (ESR, or “sed rate”) and C-reactive protein (CRP) levels, which, when elevated, suggest inflammation.
- Imaging studies: Ultrasound or magnetic resonance imaging (MRI) may be used to detect inflammation in structures around the joints.
POLYMYALGIA RHEUMATICA

- **Biopsy:** If your doctor suspects inflammation of the blood vessels, such as in GCA, you may undergo a biopsy. This involves surgical removal of a segment of an artery in the temple, which is sent to a laboratory and examined for signs of inflammation.

**Treatment**

PMR is primarily treated with low doses of corticosteroids to control inflammation and pain. Most patients experience symptom relief within a few days, at which time the dose may be gradually lowered. A maintenance dose is usually required for several months up to a few years. Higher doses may be prescribed for people with recurring headaches or other symptoms suggestive of GCA.

Researchers have been studying the effects of immunosuppressant drugs such as methotrexate in treating PMR, but results are not conclusive. The biologic drug tocilizumab has already been approved by the U.S. Food and Drug Administration for treatment of RA and GCA. (Biologic medications are complex proteins derived from living organisms; they target certain parts of the immune system to control inflammation.) More research is needed to determine the long-term safety and effectiveness of these drugs for the treatment of PMR.

In addition to medication, regular exercise is an important component of the treatment plan, especially low-impact activities such as walking, swimming, or riding a stationary bicycle. Physical therapy may be helpful in maintaining mobility and reducing discomfort.

**Side effects**

Corticosteroids carry the risk of serious side effects, such as potential bone loss (osteoporosis), cataracts, glaucoma, and increased chance of infection, among others. Therefore, it’s important to see your doctor for regular checkups. Medications may be prescribed to offset side effects. Infection prevention is also very important. Talk to your doctor about getting a flu shot, pneumonia vaccination, and/or shingles vaccination, which can reduce your risk of infection.

**Relapse**

Even with effective treatment, relapses can occur with PMR. If your symptoms return, or you develop new ones, report them to your doctor as soon as possible. Regular doctor visits and ongoing monitoring are important in detecting relapses and preventing complications.

**Your medical team**

Effective treatment of PMR may require the coordinated efforts and ongoing care of a team of medical providers and specialists. In addition to a primary care provider, you may need to see the following specialists: rheumatologist (joints, muscles, immune system); ophthalmologist (eyes); or others. The best way to manage your disease is to actively partner with your health care providers. Get to know the members of your health care team. It may be helpful to keep a health care journal to track your medications, symptoms, test results and notes from doctor appointments in one place. To get the most
POLYMYALGIA RHEUMATICA

out of your doctor visits, make a list of questions beforehand and bring along a supportive friend or family member if necessary to provide a second set of ears and take notes.

Remember, it’s up to you to be your own advocate. If you have concerns with your treatment plan, be sure to speak with your medical team. It’s always your right to seek a second opinion.

Living with PMR
Living with a chronic disease such as PMR can be challenging at times. Fatigue, pain, emotional stress, and medication side effects can take a toll on your sense of well-being, affecting relationships, work and other aspects of your daily life. Sharing your experience with family and friends, connecting with others through a support group, or talking with a mental health professional can help.

Outlook
People with PMR typically respond well to treatment, and most eventually recover entirely from the disease within one to five years. With appropriate treatment and regular follow-up care, individuals with PMR, and even those who develop GCA, can experience a full and productive life.

Recently, it has been recognized that patients with PMR are at higher risk for atherosclerosis, or hardening of the arteries, although life expectancy overall does not appear to be affected.

Clinical studies are ongoing at multicenter research centers, including the Vasculitis Clinical Research Consortium (VCRC), to better understand the risk factors and causes of vasculitis, investigate more effective and safer treatments, and work toward a cure. The Vasculitis Foundation encourages patients to consider participating in clinical research studies to help further understanding of vasculitis. Patients are also encouraged to join the Vasculitis Patient Powered Research Network (VPPRN), where they can provide valuable disease insight and information.

For more information on vasculitis research, visit: www.vasculitisfoundation.org/research
POLYMYALGIA RHEUMATICA

About Vasculitis
Vasculitis is a family of nearly 20 rare diseases characterized by inflammation of the blood vessels, which can restrict blood flow and damage vital organs and tissues. Vasculitis is classified as an autoimmune disorder, which occurs when the body’s natural defense system mistakenly attacks healthy tissues. Triggers may include infection, medication, genetic or environmental factors, allergic reactions, or another disease. However, the exact cause is often unknown.

A Family of Diseases
- Anti-GBM (Goodpasture’s) disease
- Aortitis
- Behcet’s syndrome
- Central nervous system vasculitis
- Cogan’s syndrome
- Cryoglobulinemia
- Cutaneous small-vessel vasculitis (formerly hypersensitivity/leukocytoclastic)
- Eosinophilic granulomatosi with polyangiitis (EGPA, formerly Churg-Strauss syndrome)
- Giant cell arteritis
- Granulomatosis with polyangiitis (GPA, formerly Wegener’s)
- IgA vasculitis (Henoch-Schönlein Purpura)
- Kawasaki disease
- Microscopic polyangiitis
- Polyarteritis nodosa
- Polymyalgia rheumatica
- Rheumatoid vasculitis
- Takayasu’s arteritis
- Urticarial vasculitis

About the Vasculitis Foundation
The Vasculitis Foundation (VF) is the leading organization in the world dedicated to diagnosing, treating, and curing all forms of vasculitis. The VF provides a wide range of education, awareness and research programs and services. To learn more, and get the most updated disease and treatment information, visit www.vasculitisfoundation.org

Connect with the VF on Social Media
- Instagram: vasculitisfoundation
- Twitter: @VasculitisFound
- VF Facebook Discussion Group: www.facebook.com/groups/vasculitisfoundation
POLYMYALGIA RHEUMATICA

Ways to Get Involved

- Participate in research
- Join social media
- Host or participate in an event
- Attend a regional conference and/or symposium
- Give a donation toward long-term solutions
- Become an advocate for yourself, or for others
- Share your journey

Vasculitis Foundation Mission

Building upon the collective strength of the vasculitis community, the Foundation supports, inspires and empowers individuals with vasculitis, and their families, through a wide range of education, research, clinical, and awareness initiatives.

Join the VPPRN!

The Vasculitis Patient-Powered Research Network (VPPRN) seeks to improve the care and health of patients with vasculitis by exploring research questions that matter most to patients, and by advancing medical knowledge about vasculitis. For more information, visit: www.VPPRN.org

The Vasculitis Clinical Research Consortium (VCRC) is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research in different forms of vasculitis. For more information, visit: www.rarediseasesnetwork.org/cms/vcrc

Vasculitis Foundation

PO Box 28660
Kansas City, Missouri, 64188-8660
USA
Phone: 816.436.8211
Toll-free: 800.277.9474
Fax: 816.656.3838
www.VasculitisFoundation.org
Email: vf@vasculitisfoundation.org

The VF gratefully acknowledges Alexandra Villa-Forte, MD, MPH, Cleveland Clinic, for her expertise and contribution to this brochure. This brochure was supported by an unrestricted education grant from Genentech. The Vasculitis Foundation is solely responsible for all content.

The Vasculitis Foundation (VF) is a 501(c)(3) nonprofit organization governed by a Board of Directors and advised on medical issues by a Medical and Scientific Advisory Board. VF’s educational materials are not intended to replace the counsel of a physician. VF does not endorse any medications, products or treatments for vasculitis, and advises you to consult a physician before initiating any treatment.

(Updated October 2018)